Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126112902 | 12611290 | 2 | F | 20160805 | 20160801 | 20160815 | EXP | DE-BAUSCH-BL-2016-018284 | BAUSCH AND LOMB | KRUGER T, JOCKERS-SCHERUBL M, GROHMANN R, RUTHER E, DEGNER D. DEVELOPMENT OF EPILEPTIC SEIZURES UNDER THERAPY WITH OLANZAPINE AND VENLAFAXINE ER WITH FATAL OUTCOME. PSYCHOPHARMAKOTHERAPIE. 2016;23 (3):125-128. | 76.00 | YR | F | Y | 0.00000 | 20160815 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126112902 | 12611290 | 1 | PS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Unknown | 90071 | |||||||||||
| 126112902 | 12611290 | 2 | SS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Unknown | 90071 | 37.5 | MG | |||||||||
| 126112902 | 12611290 | 3 | SS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Unknown | 90071 | |||||||||||
| 126112902 | 12611290 | 4 | SS | OLANZAPINE. | OLANZAPINE | 1 | Unknown | AT NIGHT | 0 | 5 | MG | QD | |||||||
| 126112902 | 12611290 | 5 | SS | OLANZAPINE. | OLANZAPINE | 1 | Unknown | SECOND DAY OF TREATMENT | 0 | 2.5 | MG | ||||||||
| 126112902 | 12611290 | 6 | SS | LORAZEPAM. | LORAZEPAM | 1 | Unknown | 17794 | .5 | MG | BID | ||||||||
| 126112902 | 12611290 | 7 | SS | LORAZEPAM. | LORAZEPAM | 1 | Unknown | 17794 | |||||||||||
| 126112902 | 12611290 | 8 | SS | LORAZEPAM. | LORAZEPAM | 1 | Unknown | 17794 | |||||||||||
| 126112902 | 12611290 | 9 | SS | LORAZEPAM. | LORAZEPAM | 1 | Unknown | 17794 | |||||||||||
| 126112902 | 12611290 | 10 | SS | LORAZEPAM. | LORAZEPAM | 1 | Unknown | 17794 | |||||||||||
| 126112902 | 12611290 | 11 | SS | DABIGATRAN | DABIGATRAN | 1 | Oral | 0 | |||||||||||
| 126112902 | 12611290 | 12 | SS | PRADAXA | DABIGATRAN ETEXILATE MESYLATE | 1 | Oral | 0 | |||||||||||
| 126112902 | 12611290 | 13 | C | METHOTREXATE. | METHOTREXATE | 1 | 0 | ||||||||||||
| 126112902 | 12611290 | 14 | C | PREDNISOLONE. | PREDNISOLONE | 1 | 0 | ||||||||||||
| 126112902 | 12611290 | 15 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 126112902 | 12611290 | 16 | C | FESOTERODINE | FESOTERODINE | 1 | 0 | ||||||||||||
| 126112902 | 12611290 | 17 | C | CALCIUM | CALCIUM | 1 | 0 | ||||||||||||
| 126112902 | 12611290 | 18 | C | COLECALCIFEROL | CHOLECALCIFEROL | 1 | 0 | /wk |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126112902 | 12611290 | 1 | Antidepressant therapy |
| 126112902 | 12611290 | 4 | Insomnia |
| 126112902 | 12611290 | 5 | Merycism |
| 126112902 | 12611290 | 6 | Depression |
| 126112902 | 12611290 | 11 | Anticoagulant therapy |
| 126112902 | 12611290 | 12 | Deep vein thrombosis |
| 126112902 | 12611290 | 13 | Rheumatoid arthritis |
| 126112902 | 12611290 | 14 | Product used for unknown indication |
| 126112902 | 12611290 | 15 | Product used for unknown indication |
| 126112902 | 12611290 | 16 | Product used for unknown indication |
| 126112902 | 12611290 | 17 | Product used for unknown indication |
| 126112902 | 12611290 | 18 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126112902 | 12611290 | OT |
| 126112902 | 12611290 | LT |
| 126112902 | 12611290 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126112902 | 12611290 | Seizure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |